Diammonium glycyrrhizinate preparation for liver function recovery in chronic hepatitis B in China: a meta-analysis with trial sequential analysis

The treatment of chronic hepatitis B (CHB) comprises a global medical problem, and the first-line clinical drugs have obvious shortcomings. The use of the plant extract diammonium glycyrrhizinate (DG) in food and medicine has gradually widened because of its safety and effectiveness. In clinical pra...

Full description

Saved in:
Bibliographic Details
Published inCurrent pharmaceutical design
Main Authors Liu, Yibo, Guo, Wenfang, Li, Minhui
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.01.2022
Subjects
Online AccessGet more information

Cover

Loading…
Abstract The treatment of chronic hepatitis B (CHB) comprises a global medical problem, and the first-line clinical drugs have obvious shortcomings. The use of the plant extract diammonium glycyrrhizinate (DG) in food and medicine has gradually widened because of its safety and effectiveness. In clinical practice, DG is mainly used for liver-disease treatment, but DG intervention for CHB lacks systematic-based evidence. The included randomized controlled trials were analyzed by comparator and control respectively for alanine aminotransferase (ALT), aspartate transaminase (AST), and total bilirubin (TBIL) levels, hepatitis B virus DNA negative conversion ratio, and total effective rate, and subgroup analysis was conducted for intervention time, intervention dosage form, comparator drug, and combination drug, among others. Trial sequential analysis was used to verify the results. DG could effectively reduce ALT, AST, TBIL, and other liver-function indexes and had a definite effect on liver-function recovery. From the beginning of intervention to 3 months, the effect was significantly better than that of conventional treatment. Compared with other drugs, different dosage forms had differences in efficacy, and DG enteric-coated capsules and injections were lower than compound glycyrrhizin and magnesium isoglycyrrhizin. Meanwhile DG capsules had no significant difference with them. Meanwhile, trial sequential analysis of the main results confirmed the reliability of the conclusion. To our knowledge, this was the first relatively complete meta-analysis and systematic evaluation of the efficacy of DG intervention for CHB; liver-function recovery was discussed in the context of traditional Chinese medicine thinking, and DG's therapeutic effect in CHB was defined.
AbstractList The treatment of chronic hepatitis B (CHB) comprises a global medical problem, and the first-line clinical drugs have obvious shortcomings. The use of the plant extract diammonium glycyrrhizinate (DG) in food and medicine has gradually widened because of its safety and effectiveness. In clinical practice, DG is mainly used for liver-disease treatment, but DG intervention for CHB lacks systematic-based evidence. The included randomized controlled trials were analyzed by comparator and control respectively for alanine aminotransferase (ALT), aspartate transaminase (AST), and total bilirubin (TBIL) levels, hepatitis B virus DNA negative conversion ratio, and total effective rate, and subgroup analysis was conducted for intervention time, intervention dosage form, comparator drug, and combination drug, among others. Trial sequential analysis was used to verify the results. DG could effectively reduce ALT, AST, TBIL, and other liver-function indexes and had a definite effect on liver-function recovery. From the beginning of intervention to 3 months, the effect was significantly better than that of conventional treatment. Compared with other drugs, different dosage forms had differences in efficacy, and DG enteric-coated capsules and injections were lower than compound glycyrrhizin and magnesium isoglycyrrhizin. Meanwhile DG capsules had no significant difference with them. Meanwhile, trial sequential analysis of the main results confirmed the reliability of the conclusion. To our knowledge, this was the first relatively complete meta-analysis and systematic evaluation of the efficacy of DG intervention for CHB; liver-function recovery was discussed in the context of traditional Chinese medicine thinking, and DG's therapeutic effect in CHB was defined.
Author Li, Minhui
Liu, Yibo
Guo, Wenfang
Author_xml – sequence: 1
  givenname: Yibo
  surname: Liu
  fullname: Liu, Yibo
  organization: Institute Mongolia Medical University, Hohhot , China
– sequence: 2
  givenname: Wenfang
  surname: Guo
  fullname: Guo, Wenfang
  organization: Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot , China
– sequence: 3
  givenname: Minhui
  surname: Li
  fullname: Li, Minhui
  organization: Baotou Medical College, Baotou , China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35593360$$D View this record in MEDLINE/PubMed
BookMark eNo1kEtOwzAURS0Eoh_YAjILCPgbO8yg5SdVYgLjykleiFHiBMcBhWWwYlygo3d1j94Z3AU6dJ0DhM4puWBUiUvKNU0p00ynacoYEYxSLjJKDtCcasUTEckMLYbhjRDKMiqO0YxLmXGekjn6XlvTtp2zY4tfm6mYvK_tl3UmAO499MabYDuHq87jxn6Ax9Xoit_KQ9HFYsLW4aL20VHgOn4EG-yAb3b1qo6mK2xwC8EkxplmGiL7tKHGwVvT4AHeR3BhF_f4BB1Vphng9P8u0cvd7fPqIdk83T-urjdJLjQLiRayjAPkxigigWkACrnWPFdQplVWlEYoVVW8klBmquQxSkoMJ7JUBcklW6KzP28_5i2U297b1vhpux-H_QA_DW0b
CitedBy_id crossref_primary_10_1016_j_phymed_2023_154883
crossref_primary_10_1016_j_toxicon_2024_107795
crossref_primary_10_1097_SHK_0000000000002353
crossref_primary_10_1016_j_intimp_2024_113374
ContentType Journal Article
Copyright Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Copyright_xml – notice: Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
DBID NPM
DOI 10.2174/1381612828666220421134910
DatabaseName PubMed
DatabaseTitle PubMed
DatabaseTitleList PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-4286
ExternalDocumentID 35593360
Genre Meta-Analysis
GroupedDBID ---
.5.
0R~
29F
36B
4.4
53G
5GY
AAEGP
ABEEF
ABJNI
ABVDF
ACGFO
ACGFS
ACITR
ACIWK
ACPRK
ACZAY
AENEX
AFRAH
AFUQM
AGJNZ
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ANTIV
CS3
DU5
EBS
F5P
GH2
HZ~
IPNFZ
KCGFV
KFI
NPM
O9-
P2P
RIG
ID FETCH-LOGICAL-b482t-845d174baa705e28ee1eb883b7ed6f9cda477ff3f5ed97d3ff3510a305d7c0b52
IngestDate Thu Jan 02 22:56:28 EST 2025
IsPeerReviewed true
IsScholarly true
Keywords chronic hepatitis B
meta-analysis
ALT
TSA
diammonium glycyrrhizinate
TCM
Language English
License Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-b482t-845d174baa705e28ee1eb883b7ed6f9cda477ff3f5ed97d3ff3510a305d7c0b52
PMID 35593360
ParticipantIDs pubmed_primary_35593360
PublicationCentury 2000
PublicationDate 2022-01-01
PublicationDateYYYYMMDD 2022-01-01
PublicationDate_xml – month: 01
  year: 2022
  text: 2022-01-01
  day: 01
PublicationDecade 2020
PublicationPlace United Arab Emirates
PublicationPlace_xml – name: United Arab Emirates
PublicationTitle Current pharmaceutical design
PublicationTitleAlternate Curr Pharm Des
PublicationYear 2022
SSID ssj0012914
Score 2.3992758
SecondaryResourceType review_article
Snippet The treatment of chronic hepatitis B (CHB) comprises a global medical problem, and the first-line clinical drugs have obvious shortcomings. The use of the...
SourceID pubmed
SourceType Index Database
Title Diammonium glycyrrhizinate preparation for liver function recovery in chronic hepatitis B in China: a meta-analysis with trial sequential analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/35593360
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBabFkIupen7kTKFksvGrVeWLbu3JG0JpS05bGhuQbKkrCDrLIn3sKG_or-4I8lee5cG0l6MmVm8RvOheXjmEyHvDGOKZlpFXMsyYrlQUZGURcSoiI02yqSJG07-_iM7OmFfT9PTweBXf7qklu_Lm7_OlfyPVVGGdnVTsv9g2eVDUYD3aF-8ooXxeicbf7LC_ZmdT4fnF4tycXU1sTe2wvDRzf4HVu-mk_DC9V8MnRfzIpcHo8AP_ZWBHxdjRtddXdvr4YGfBXQna4dZ6KmuRSRa-pJQuvWnfYRG7Np6woGg7ke7LfnTbLJSOFcrXSPf7Nz7ASsvl81Ac1_A_akrIxrP6n8Y-vyrydz2ixWU9ooVOmywOU8QCIH-en37dumRqyS4j5kjlwtibkUpbisjR6IY2l97Zp1NvV0xYiqSJLuDdo1Zu1VtkA3MMdyhqa7S03yBosWIbZK3zVt9uPWdtshm-5y1zMRHKOOH5EGTWsB-wMk2GejqEdk9Dmu_2INxN2p3vQe7cNyxli8ek98dmGANTNADEyCYwIMJWjBBCyawFTRggiWY4MCJPZg-goAVKIGDEngoQQclaNVPyMmXz-PDo6g5sCOSLKd1lLNU4WJJIXicapprPdIyzxPJtcpMUSrBODcmMalWBVcJ3qJLEOhyFC9jmdKn5F51WennBFiWF2XKTZwKyZSJJS8TnaVaZrGmSscvyLOw1mezwMpy1lrh5a2aV2Srw-Rrct_gNqB3MKas5Rtv_D_Gn32D
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diammonium+glycyrrhizinate+preparation+for+liver+function+recovery+in+chronic+hepatitis+B+in+China%3A+a+meta-analysis+with+trial+sequential+analysis&rft.jtitle=Current+pharmaceutical+design&rft.au=Liu%2C+Yibo&rft.au=Guo%2C+Wenfang&rft.au=Li%2C+Minhui&rft.date=2022-01-01&rft.eissn=1873-4286&rft_id=info:doi/10.2174%2F1381612828666220421134910&rft_id=info%3Apmid%2F35593360&rft_id=info%3Apmid%2F35593360&rft.externalDocID=35593360